München (ots) - Ab sofort verstärken Christiane Ritter, Tim Jungblut und Sebastian Schütze das Team von ...
AmVac AG Expands Its Advisory Board with Hartmut Retzlaff, CEO of STADA Arzneimittel AG
Zug (ots) - The Swiss company AmVac AG, a biopharmaceutical company based in Zug, has announced the expansion of its Advisory Board. With the acquisition of Hartmut Retzlaff, CEO of STADA Arzneimittel AG, AmVac now has one of the most successful company managers in the German pharmaceutical industry on the Board. Hartmut Retzlaff has been head of STADA AG since 1994 and was responsible for its successful flotation in 1998. STADA has been listed on the M-Dax since 2001 and today has a market capitalization of approximately EUR 2.7 billion. STADA focuses on the development and marketing of products with unpatented active pharmaceutical ingredients in the health and pharmaceuticals market. In the 2007 fiscal year, STADA recorded sales of EUR 1.6 billion and a net profit of EUR 105 million.
Melinda-Kinga Karpati, CEO of AmVac AG, says, "In Hartmut Retzlaff we have acquired one of the most experienced managers for AmVac AG. We are looking forward to constructive collaboration with him and are counting on his extensive network."
About AmVac AG
AmVac AG is a biopharmaceutical company based in Switzerland. The company focuses on the vaccine market which is displaying above-average growth rates. Its pipeline includes two close-to-market therapeutic vaccines in the fields of gynecology and urology. Other innovative vaccines and technologies are under development. The well-known market research company Frost & Sullivan presented its sought-after Enabling Technology of the Year Award to AmVac AG in 2006.
ots Originaltext: AmVac AG
Ariane Meynert, Head of PR/IR